Stupak will retire
This article was originally published in The Tan Sheet
Executive SummaryHouse Oversight and Investigations Subcommittee Chairman Bart Stupak, an 18-year member of Congress and a frequent critic of FDA's record for food and drug safety, says he will not seek reelection. At an April 9 press conference at his congressional district in Michigan, the Democrat said he has served the public more than 30 years, beginning as a police officer in Escanaba, Mich., and later as a State Police trooper, before becoming a state representative and later a member of Congress. Like his recognized mentor, fellow Michigan Democrat John Dingell, Stupak said health care reform was a priority for him from the beginning, and stressed the significance of the recent passage of reform legislation (1"The Tan Sheet" March 29, 2010). "I've worked alongside my colleagues to achieve health care reform and I'm proud to have helped bring it across the finish line," he said, adding, "I felt that my main legislative goal was accomplished." Potential candidates have until May 11 to file to campaign for the office
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.